Cancer Research Cancer Genome no Abstract
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 7275-7283, August 1, 2007. doi: 10.1158/0008-5472.CAN-06-2369
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caslini, C.
Right arrow Articles by Hess, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caslini, C.
Right arrow Articles by Hess, J. L.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Interaction of MLL Amino Terminal Sequences with Menin Is Required for Transformation

Corrado Caslini1, Zhaohai Yang2, Mohamad El-Osta1, Thomas A. Milne3, Robert K. Slany4 and Jay L. Hess1

1 Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; 2 Department of Pathology, University of Alabama, Birmingham, Alabama; 3 Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York; and 4 Department of Genetics, University of Erlangen, Erlangen, Germany

Requests for reprints: Jay L. Hess, Department of Pathology, University of Michigan Medical School, 5240 Medical Science I, 1301 Catherine Avenue, Ann Arbor, MI 48109-0602. Phone: 734-763-6384; Fax: 734-763-4782; E-mail: jayhess{at}med.umich.edu.

Rearrangements of the mixed lineage leukemia gene MLL are associated with aggressive lymphoid and myeloid leukemias. The resulting MLL fusion proteins enforce high-level expression of HOX genes and the HOX cofactor MEIS1, which is pivotal for leukemogenesis. Both wild-type MLL and MLL fusion proteins interact with the tumor suppressor menin and with the Hoxa9 locus in vivo. Here, we show that MLL sequences between amino acids 5 and 44 are required for interaction with menin and for the transformation of hematopoietic progenitors. Blocking the MLL-menin interaction by the expression of a dominant negative inhibitor composed of amino terminal MLL sequences down-regulates Meis1 expression and inhibits cell proliferation, suggesting that targeting this interaction may be an effective therapeutic strategy for leukemias with MLL rearrangements. [Cancer Res 2007;67(15):7275–83]




This article has been cited by other articles:


Home page
Genes Dev.Home page
B. Argiropoulos, E. Yung, and R. K. Humphries
Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis
Genes & Dev., November 15, 2007; 21(22): 2845 - 2849.
[Full Text] [PDF]


Home page
Genes Dev.Home page
P. Wong, M. Iwasaki, T. C.P. Somervaille, C. W. E. So, and M. L. Cleary
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential
Genes & Dev., November 1, 2007; 21(21): 2762 - 2774.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.